BR9812114A - Substituted phenylalanine-type compounds that inhibit vla-4-mediated leukocyte adhesion - Google Patents

Substituted phenylalanine-type compounds that inhibit vla-4-mediated leukocyte adhesion

Info

Publication number
BR9812114A
BR9812114A BR9812114-6A BR9812114A BR9812114A BR 9812114 A BR9812114 A BR 9812114A BR 9812114 A BR9812114 A BR 9812114A BR 9812114 A BR9812114 A BR 9812114A
Authority
BR
Brazil
Prior art keywords
compounds
leukocyte adhesion
vla
mediated leukocyte
inhibit
Prior art date
Application number
BR9812114-6A
Other languages
Portuguese (pt)
Inventor
Eugene D Thorsett
Christopher M Semko
Dimitrios Sarantakis
Michael A Pleiss
Louis Joh Lombardo
Andrei W Konradi
Anthony Kreft
Francine S Grant
Darren B Dressen
Michael S Dappen
Reinhardt Bernhard Baudy
Susan Ashwell
Original Assignee
Elan Pharm Inc
American Home Prod
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Pharm Inc, American Home Prod filed Critical Elan Pharm Inc
Publication of BR9812114A publication Critical patent/BR9812114A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/0606—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing heteroatoms not provided for by C07K5/06086 - C07K5/06139, e.g. Ser, Met, Cys, Thr
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C07K5/06165—Dipeptides with the first amino acid being heterocyclic and Pro-amino acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Patente de Invenção: <B>"COMPOSTOS DO TIPO FENILALANINA SUBSTITUìDA QUE INIBEM A ADESãO DE LEUCóCITO MEDIADA POR VLA-4"<D>. São divulgados compostos que ligam-se ao VLA-4. Certos destes compostos também inibem a adesão de leucócito e, em particular, adesão de leucócito mediada por VLA-4. Tais compostos, são úteis no tratamento de doenças inflamatórias em um paciente mamífero, por exemplo, humano, como a asma, doença de Alzheimer, ateroesclerose, demência da AIDS, diabetes, doença inflamatória do intestino, artrite reumatóide, transplante de tecido, metástase de tumor e esquemia miocardial. Os compostos são também administrados para o tratamento de doenças inflamatórias do cérebro, tais como esclerose múltipla.Invention Patent: <B> "SUBSTITUTED PHENYLALANINE TYPE COMPOUNDS THAT INHIBIT VLA-4 MEDIATED LEUKOCYTE ADHESION" <D>. Compounds that bind to VLA-4 are disclosed. Certain of these compounds also inhibit leukocyte adhesion and, in particular, VLA-4 mediated leukocyte adhesion. Such compounds are useful in the treatment of inflammatory diseases in a mammalian, for example, human patient, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, metastasis of myocardial tumor and scemia. The compounds are also administered for the treatment of inflammatory diseases of the brain, such as multiple sclerosis.

BR9812114-6A 1997-07-31 1998-07-30 Substituted phenylalanine-type compounds that inhibit vla-4-mediated leukocyte adhesion BR9812114A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92039497A 1997-07-31 1997-07-31
PCT/US1998/015313 WO1999006431A1 (en) 1997-07-31 1998-07-30 Substituted phenylalanine type compounds which inhibit leukocyte adhesion mediated by vla-4

Publications (1)

Publication Number Publication Date
BR9812114A true BR9812114A (en) 2000-07-18

Family

ID=25443662

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9812114-6A BR9812114A (en) 1997-07-31 1998-07-30 Substituted phenylalanine-type compounds that inhibit vla-4-mediated leukocyte adhesion

Country Status (16)

Country Link
EP (1) EP1001972A1 (en)
JP (1) JP2001512134A (en)
KR (1) KR20010022411A (en)
CN (1) CN1133648C (en)
AR (1) AR013384A1 (en)
AU (1) AU756696B2 (en)
BR (1) BR9812114A (en)
CA (1) CA2290747A1 (en)
HU (1) HUP0004259A3 (en)
IL (1) IL133640A0 (en)
NO (1) NO20000450L (en)
NZ (1) NZ502582A (en)
PL (1) PL338423A1 (en)
TW (1) TW534910B (en)
WO (1) WO1999006431A1 (en)
ZA (1) ZA986827B (en)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6903075B1 (en) 1997-05-29 2005-06-07 Merck & Co., Inc. Heterocyclic amide compounds as cell adhesion inhibitors
US6291511B1 (en) 1997-05-29 2001-09-18 Merck & Co., Inc. Biarylalkanoic acids as cell adhesion inhibitors
WO1998054207A1 (en) * 1997-05-30 1998-12-03 Celltech Therapeutics Limited Anti-inflammatory tyrosine derivatives
JP2001517246A (en) 1997-06-23 2001-10-02 田辺製薬株式会社 α ▲ Lower 4 ▼ β ▲ Lower 1 ▼ Inhibitor of cell adhesion
US6197794B1 (en) * 1998-01-08 2001-03-06 Celltech Therapeutics Limited Phenylalanine derivatives
MY153569A (en) 1998-01-20 2015-02-27 Mitsubishi Tanabe Pharma Corp Inhibitors of ?4 mediated cell adhesion
US6329372B1 (en) 1998-01-27 2001-12-11 Celltech Therapeutics Limited Phenylalanine derivatives
ES2226413T3 (en) 1998-02-26 2005-03-16 Celltech Therapeutics Limited PHENYLALANINE DERIVATIVES AS INTEGRIN ALFA-4 INHIBITORS.
US6521626B1 (en) 1998-03-24 2003-02-18 Celltech R&D Limited Thiocarboxamide derivatives
GB9811159D0 (en) * 1998-05-22 1998-07-22 Celltech Therapeutics Ltd Chemical compounds
GB9811969D0 (en) 1998-06-03 1998-07-29 Celltech Therapeutics Ltd Chemical compounds
US6685617B1 (en) 1998-06-23 2004-02-03 Pharmacia & Upjohn Company Inhibitors of α4β1 mediated cell adhesion
GB9814414D0 (en) 1998-07-03 1998-09-02 Celltech Therapeutics Ltd Chemical compounds
US6333340B1 (en) * 1998-08-14 2001-12-25 Gpi Nil Holdings, Inc. Small molecule sulfonamides for vision and memory disorders
US6339101B1 (en) * 1998-08-14 2002-01-15 Gpi Nil Holdings, Inc. N-linked sulfonamides of N-heterocyclic carboxylic acids or isosteres for vision and memory disorders
GB9821061D0 (en) 1998-09-28 1998-11-18 Celltech Therapeutics Ltd Chemical compounds
GB9821222D0 (en) 1998-09-30 1998-11-25 Celltech Therapeutics Ltd Chemical compounds
US7396526B1 (en) 1998-11-12 2008-07-08 Johnson & Johnson Consumer Companies, Inc. Skin care composition
GB9825652D0 (en) 1998-11-23 1999-01-13 Celltech Therapeutics Ltd Chemical compounds
GB9826174D0 (en) 1998-11-30 1999-01-20 Celltech Therapeutics Ltd Chemical compounds
ES2339738T3 (en) 1999-01-22 2010-05-25 Elan Pharmaceuticals, Inc. DERIVATIVES OF ACILO WHICH TREAT DISORDERS RELATED TO VLA-4.
AR035476A1 (en) 1999-01-22 2004-06-02 Elan Pharm Inc HETEROARILO AND HETEROCICLIC COMPOUNDS WITH FUSIONED RING, WHICH INHIBIT THE ADHESION OF LEUKOCYTES THROUGH VLA-4, PHARMACEUTICAL COMPOSITIONS, THE USE OF THE SAME FOR THE MANUFACTURE OF A MEDICINAL PRODUCT AND A BIOLOGICAL METHOD 4
US6436904B1 (en) 1999-01-25 2002-08-20 Elan Pharmaceuticals, Inc. Compounds which inhibit leukocyte adhesion mediated by VLA-4
JP2002539080A (en) * 1999-01-25 2002-11-19 エラン ファーマシューティカルズ，インコーポレイテッド Compounds that inhibit leukocyte adhesion mediated by VLA-4
US6518283B1 (en) 1999-05-28 2003-02-11 Celltech R&D Limited Squaric acid derivatives
GEP20063956B (en) * 1999-08-13 2006-11-10 Biogen Idec Inc Cell adhesion inhibitors
US6534513B1 (en) 1999-09-29 2003-03-18 Celltech R&D Limited Phenylalkanoic acid derivatives
US6455539B2 (en) 1999-12-23 2002-09-24 Celltech R&D Limited Squaric acid derivates
AP2002002565A0 (en) 1999-12-28 2002-06-30 Pfizer Prod Inc Non-peptidyl inhibitors of VLA-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases.
WO2001079173A2 (en) 2000-04-17 2001-10-25 Celltech R & D Limited Enamine derivatives as cell adhesion molecules
US6403608B1 (en) 2000-05-30 2002-06-11 Celltech R&D, Ltd. 3-Substituted isoquinolin-1-yl derivatives
US6545013B2 (en) 2000-05-30 2003-04-08 Celltech R&D Limited 2,7-naphthyridine derivatives
WO2002004426A1 (en) 2000-07-07 2002-01-17 Celltech R & D Limited Squaric acid derivatives containing a bicyclic heteroaromatic ring as integrin antagonists
EP1305291A1 (en) 2000-08-02 2003-05-02 Celltech R&amp;D Limited 3-substituted isoquinolin-1-yl derivatives
WO2002016329A1 (en) 2000-08-18 2002-02-28 Ajinomoto Co., Inc. Novel phenylalanine derivatives
MY129000A (en) 2000-08-31 2007-03-30 Tanabe Seiyaku Co INHIBITORS OF a4 MEDIATED CELL ADHESION
US6607735B2 (en) 2000-12-21 2003-08-19 Johnson & Johnson Consumer Companies, Inc. Method for reducing the appearance of dark circles under the eyes
JP2004526733A (en) * 2001-03-20 2004-09-02 メルク　エンド　カムパニー　インコーポレーテッド Substituted N-arylsulfonyl-proline derivatives as potent cell adhesion inhibitors
DE10127126A1 (en) * 2001-06-05 2002-12-19 Forschungszentrum Juelich Gmbh New protected O-(2-substituted ethyl)-L-tyrosine derivatives, useful as intermediates for the positron emission tomography contrast agent O-(2-(18F)-fluoroethyl)-L-tyrosine
MY140707A (en) 2002-02-28 2010-01-15 Mitsubishi Tanabe Pharma Corp Process for preparing a phenylalanine derivative and intermediates thereof
TW200307671A (en) 2002-05-24 2003-12-16 Elan Pharm Inc Heteroaryl compounds which inhibit leukocyte adhesion mediated by α 4 integrins
TWI281470B (en) 2002-05-24 2007-05-21 Elan Pharm Inc Heterocyclic compounds which inhibit leukocyte adhesion mediated by alpha4 integrins
EP1592387A4 (en) 2003-01-24 2009-05-06 Elan Pharm Inc Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents
JP2007526230A (en) * 2003-06-25 2007-09-13 エラン ファーマシューティカルズ，インコーポレイテッド Methods and compositions for treating rheumatoid arthritis
EP2803667A1 (en) 2003-12-22 2014-11-19 Ajinomoto Co., Inc. Phenylalanine derivatives
EP2124996A4 (en) 2007-02-20 2010-03-24 Merrimack Pharmaceuticals Inc Methods of treating multiple sclerosis by administration of alpha-fetoprotein in combination with an integrin antagonist
EP2288715B1 (en) 2008-04-11 2014-09-24 Merrimack Pharmaceuticals, Inc. Human serum albumin linkers and conjugates thereof
CN102137836B (en) * 2008-07-28 2015-08-26 赛丹思科大学 Be used for the treatment of the compound of metabolic trouble
JP2017510627A (en) 2014-03-13 2017-04-13 プロセナ バイオサイエンシーズ リミテッド Combined treatment of multiple sclerosis
EP3873605A1 (en) 2018-10-30 2021-09-08 Gilead Sciences, Inc. Compounds for inhibition of alpha4beta7 integrin
CN112969687A (en) 2018-10-30 2021-06-15 吉利德科学公司 Quinoline derivatives as alpha 4 beta 7 integrin inhibitors
AU2019373244B2 (en) 2018-10-30 2022-05-26 Gilead Sciences, Inc. Imidazopyridine derivatives as alpha4beta7 integrin inhibitors
KR102652797B1 (en) 2018-10-30 2024-04-02 길리애드 사이언시즈, 인코포레이티드 Compounds for inhibition of alpha4beta7 integrin
EP4013499A1 (en) 2019-08-14 2022-06-22 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA737898B (en) * 1972-11-24 1974-07-31 Hoffmann La Roche Peptides
CA1102316A (en) * 1975-12-09 1981-06-02 Shosuke Okamoto N su2 xx-arylsulfonyl-l-argininamides and the pharmaceutically acceptable salts thereof
WO1992016549A1 (en) * 1991-03-18 1992-10-01 Pentapharm Ag Parasubstituted phenylalanine derivates
AU693143B2 (en) * 1993-12-06 1998-06-25 Cytel Corporation CS-1 peptidomimetics, compositions and methods of using the same
US6306840B1 (en) * 1995-01-23 2001-10-23 Biogen, Inc. Cell adhesion inhibitors

Also Published As

Publication number Publication date
KR20010022411A (en) 2001-03-15
NZ502582A (en) 2002-07-26
TW534910B (en) 2003-06-01
HUP0004259A2 (en) 2001-04-28
PL338423A1 (en) 2000-11-06
NO20000450L (en) 2000-03-28
CN1265668A (en) 2000-09-06
AU8661198A (en) 1999-02-22
NO20000450D0 (en) 2000-01-28
AU756696B2 (en) 2003-01-23
EP1001972A1 (en) 2000-05-24
HUP0004259A3 (en) 2001-05-28
WO1999006431A1 (en) 1999-02-11
ZA986827B (en) 2000-05-02
JP2001512134A (en) 2001-08-21
AR013384A1 (en) 2000-12-27
CA2290747A1 (en) 1999-02-11
CN1133648C (en) 2004-01-07
IL133640A0 (en) 2001-04-30

Similar Documents

Publication Publication Date Title
BR9812114A (en) Substituted phenylalanine-type compounds that inhibit vla-4-mediated leukocyte adhesion
BR9811598A (en) &#34;carbamyloxy compounds that inhibit vla-4-mediated leukocyte adhesion&#34;.
BR9811569A (en) Compounds that inhibit vla-4-mediated leukocyte adhesion
BR9811594A (en) Sulphonylated dipeptide compounds that inhibit vla-4 mediated leukocyte adhesion
BR9812111A (en) Dipeptide and related compounds that inhibit vla-4-mediated leukocyte adhesion
BR9811573A (en) Benzyl compounds that inhibit vla-4 mediated leukocyte adhesion
BR9812118A (en) 4-Amino-phenylalanine-type compounds that inhibit vla-4-mediated leukocyte adhesion
BR9811599A (en) Dipetid compounds that inhibit vla-4 mediated leukocyte adhesion
BR0007663A (en) Acyl derivatives for use in the treatment of diseases related to vla-4
BRPI0513143A (en) multivalent vla-4 antagonists comprising polymeric moieties
ECSP045425A (en) HETEROCYCLIC COMPOUNDS THAT INHIBIT THE ADHESION OF LEUKOCYTES THROUGH INTEGRINS a4
EA200401561A1 (en) HETEROARRYLIC COMPOUNDS THAT INHIBIT MEDIATED ГР4-INTEGRINES leukocyte adhesion
WO2000043354A3 (en) Multicyclic compounds which inhibit leukocyte adhesion mediated by vla-4
WO2002008203A3 (en) 3-(heteroaryl) alanine derivatives-inhibitors of leukocyte adhesion mediated by vla-4
ZA200803016B (en) Carbamate compounds which inhibit leukocyte adhesion mediated by VLA-4
AU3246600A (en) Alpha-aminoacetic acid derivatives useful as alpha 4 beta 7 receptor antagonists
WO2000043371A3 (en) Fused ring heteroaryl and heterocyclic compounds which inhibit leukocyte adhesion mediated by vla-4
WO2002008201A3 (en) Beta-amino acid derivatives-inhibitors of leukocyte adhesion mediated by vla-4
WO2000043413A3 (en) Pyroglutamic acid derivatives and related compounds which inhibit leukocyte adhesion mediated by vla-4
AR029611A1 (en) COMPOUNDS THAT INHIBIT THE ADHESION OF LEUCOCITS INTERMEDIATE BY VLA-4
AR026105A1 (en) HETEROARILO, HETEROCICLICO AND ILO COMPUTERS THAT

Legal Events

Date Code Title Description
FA10 Dismissal: dismissal - article 33 of industrial property law
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]